List of Excipients in Branded Drug POSIMIR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Renaissance Lakewood LLC	POSIMIR	bupivacaine	49396-6601	BENZYL ALCOHOL	2041-01-12
Renaissance Lakewood LLC	POSIMIR	bupivacaine	49396-6601	SUCROSE ACETATE ISOBUTYRATE	2041-01-12
INNOCOLL PHARMACEUTICALS	POSIMIR	bupivacaine	51715-660	BENZYL ALCOHOL	2041-01-12
INNOCOLL PHARMACEUTICALS	POSIMIR	bupivacaine	51715-660	SUCROSE ACETATE ISOBUTYRATE	2041-01-12

POSIMIR Excipient Strategy and Commercial Opportunities

Last updated: August 10, 2026

POSIMIR is a long-acting bupivacaine formulation that uses the SABER delivery system rather than a conventional aqueous local-anesthetic vehicle. Its commercial value depends on the excipient platform, sterile manufacturing process, depot performance, and surgical workflow benefits. The principal excipient opportunity is therefore a controlled-delivery platform strategy, not a commodity supply strategy for sucrose acetate isobutyrate alone.

POSIMIR contains bupivacaine hydrochloride, sucrose acetate isobutyrate, benzyl alcohol, and ethanol. The product is FDA-approved for administration into the surgical site to produce postsurgical analgesia in adults. Each 132 mL vial contains 660 mg of bupivacaine, equivalent to 5 mg/mL [1].

What is POSIMIR and how does its excipient system work?

POSIMIR is an extended-release formulation of bupivacaine hydrochloride. Its excipient system creates a viscous depot after administration into the surgical site, allowing prolonged release of bupivacaine over several days.

Attribute	POSIMIR profile
Active ingredient	Bupivacaine hydrochloride
Drug class	Long-acting amide local anesthetic
Dosage form	Sterile injectable solution
Strength	5 mg/mL
Vial size	132 mL
Total bupivacaine	660 mg per vial
Delivery system	SABER delivery platform
Key excipient	Sucrose acetate isobutyrate, or SAIB
Other listed excipients	Benzyl alcohol and ethanol
Administration	Surgical-site infiltration
FDA pathway	505(b)(2) New Drug Application
NDA	210333
Approved use	Postsurgical analgesia in adults

The formulation is designed for local administration rather than intravenous or intramuscular dosing. The excipient system must maintain drug stability before injection, support controlled depot formation after administration, and avoid unacceptable local tissue reactions.

SAIB is the central formulation component. It is a highly viscous, hydrophobic sucrose ester that can function as a liquid depot-forming material. Ethanol and benzyl alcohol reduce viscosity and help maintain the product as an injectable solution before administration. Following exposure to physiological fluids, solvent exchange and changes in the local environment support depot formation and gradual drug release [1, 2].

Which excipients are used in POSIMIR?

The principal excipients have different technical and commercial functions.

Excipient	Likely formulation function	Commercial significance
Sucrose acetate isobutyrate	Depot-forming matrix and release-control component	Core platform material; highest strategic value
Ethanol	Solvent and viscosity modifier	Requires residual-solvent and container-closure control
Benzyl alcohol	Solvent, preservative-related formulation component, and viscosity modifier	Requires toxicological and local-tolerance assessment
Bupivacaine hydrochloride	Active pharmaceutical ingredient	Determines dose, release target, and compatibility requirements

The exact quantitative composition and manufacturing parameters are proprietary. Public labeling identifies the excipient set but does not disclose the complete formulation design space, mixing sequence, temperature profile, hold times, filling process, or release specifications [1].

The commercial distinction is important. SAIB may be available as an established food or specialty excipient, but injectable use imposes more demanding requirements. A supplier serving POSIMIR or a follow-on product must demonstrate lot-to-lot consistency, impurity control, bioburden control, traceability, and compatibility with sterile manufacturing.

Why is SAIB commercially important for POSIMIR?

SAIB is the primary source of formulation differentiation. It is not merely a bulking agent or pH adjuster. It controls the physical behavior of the product before and after administration.

SAIB creates several potential barriers to substitution:

1. Its viscosity affects filling, dose delivery, needle selection, and administration time.
2. Its ester composition affects depot formation and drug release.
3. Its interaction with ethanol and benzyl alcohol affects solution stability.
4. Its purity profile can affect local tolerability and product shelf life.
5. Its supply chain may be less mature than those for standard parenteral excipients.

A competing product using a different lipid, polymer, or in situ gel system would need to reproduce the clinical duration, injection characteristics, local safety profile, and manufacturing robustness. It would not necessarily need to use SAIB, but it would face development risk if the clinical benefit depends on the specific release profile produced by the SABER system.

What excipient supply opportunities exist around POSIMIR?

The strongest opportunities fall into five categories.

GMP-grade SAIB supply

A qualified SAIB supplier could pursue a premium-grade material strategy for parenteral depot products. The product would need tighter controls than conventional food-grade SAIB, including:

• Defined ester composition
• Low residual solvent levels
• Controlled water content
• Low peroxide and aldehyde levels
• Heavy-metal limits
• Microbial and endotoxin controls
• Traceable raw-material sourcing
• Consistent viscosity and density
• Change-control commitments suitable for an NDA product

The addressable market for POSIMIR alone is likely limited by the product's single indication and surgical use. The greater opportunity is qualification for additional depot products using the same excipient platform.

Dual sourcing and supply-chain security

SAIB supply continuity is commercially valuable because a formulation change could require comparability work, stability studies, process validation, and FDA review. A second-source supplier could generate value by offering:

• Equivalent material specifications
• Validated analytical methods
• Regulatory support packages
• Reserve inventory
• Regional manufacturing redundancy
• Technical assistance for scale-up

A second source would not automatically become commercially interchangeable. The sponsor would need to assess whether changes in supplier, grade, impurity profile, or viscosity alter product performance.

Sterile fill-finish services

POSIMIR's high viscosity and solvent-containing formulation create a specialized fill-finish opportunity. Conventional aqueous filling lines may not be suitable without equipment and process modifications.

Relevant capabilities include:

• Heated or controlled-temperature transfer
• Positive-displacement filling
• Low-shear mixing
• Solvent-compatible equipment
• Closed-system handling
• Accurate filling of viscous liquids
• Compatibility with the selected vial and stopper
• In-process control of fill weight and homogeneity

Contract manufacturers with experience in viscous injectable products could target POSIMIR-like formulations, particularly where sponsors lack dedicated equipment.

Analytical and formulation services

Specialized laboratories can support:

• SAIB identity and composition testing
• Rheology and viscosity measurement
• Drug-release testing
• Residual solvent analysis
• Extractables and leachables studies
• In vitro depot characterization
• Stability-indicating assays
• Container-closure compatibility
• In-use administration studies

Release testing is likely to be more complex than potency and sterility testing alone. A sponsor must link physical attributes such as viscosity, solvent content, and depot behavior to drug release and clinical performance.

Platform licensing

The highest-value opportunity is licensing a complete depot technology rather than selling SAIB. Potential licensees include manufacturers developing:

• Long-acting local anesthetics
• Postoperative anti-inflammatory agents
• Anti-infective surgical-site products
• Depot analgesics
• Veterinary postoperative products
• Regional formulations for markets outside the United States

A platform license can include excipient specifications, formulation know-how, manufacturing instructions, analytical methods, and regulatory support. The value is greater when the license includes a validated path for a new active ingredient.

What formulations are protected by POSIMIR-related intellectual property?

POSIMIR-related intellectual property is likely to cover more than the identity of SAIB. Relevant claim categories can include:

• Bupivacaine in a SAIB-based depot system
• Specific solvent combinations
• Drug-to-excipient ratios
• Viscosity ranges
• Release profiles
• Surgical-site administration
• Manufacturing and mixing processes
• Container-closure configurations
• Use with particular surgical procedures
• Combination treatment with other analgesics

The commercially important distinction is between composition claims and platform claims. A narrow composition claim may protect a specific bupivacaine formulation. A broader platform claim could create additional barriers for other active ingredients formulated in the same delivery system.

Current patent status must be confirmed through the FDA Orange Book, USPTO records, and applicable national registers. FDA labeling identifies POSIMIR as NDA 210333 but does not provide a complete public analysis of all formulation, manufacturing, and method-of-use rights [1]. Patent expiry, pediatric exclusivity, patent-term adjustment, terminal disclaimers, and litigation outcomes can change the practical exclusivity date.

When does POSIMIR lose exclusivity?

POSIMIR's commercial exclusivity has several components:

Exclusivity element	Relevance
New Drug Application exclusivity	The 505(b)(2) approval may carry a statutory exclusivity period depending on FDA designation
Listed patents	May delay approval or launch of an ANDA or 505(b)(2) applicant
Formulation patents	May protect the SABER-bupivacaine combination or specific release characteristics
Method-of-use patents	May cover postsurgical analgesia or specific surgical applications
Manufacturing patents	May constrain alternative production routes
Regulatory labeling	May limit the practical scope of an abbreviated product's approved use

A precise generic-entry date cannot be inferred from the approval date alone. A potential challenger would need to review Orange Book listings, patent certifications, applicable statutory stays, and any settlement agreement.

What is the Orange Book status of POSIMIR?

POSIMIR is listed in FDA drug databases as an approved prescription drug product under NDA 210333. The Orange Book is the primary source for determining whether the reference product has listed patents and whether those patents carry pediatric exclusivity or other relevant status [3].

For commercial planning, the key questions are:

• Which patents are listed against NDA 210333?
• Are the patents composition, method-of-use, or manufacturing patents?
• Which patents have expiration dates later than the statutory exclusivity period?
• Has FDA granted any pediatric extension?
• Has an ANDA or 505(b)(2) applicant submitted a Paragraph IV certification?
• Has litigation triggered a 30-month stay?
• Does any settlement permit an earlier launch?

An excipient supplier should monitor these issues because an early generic or follow-on launch could increase demand for SAIB while reducing the originator's purchasing leverage.

Which companies are challenging POSIMIR?

No company should be characterized as a POSIMIR challenger without a verified ANDA filing, Paragraph IV notice, patent litigation complaint, or public corporate disclosure. Generic bupivacaine products do not necessarily compete directly with POSIMIR because standard bupivacaine injections lack the same extended-release delivery profile.

Potential competitive categories include:

• Generic bupivacaine hydrochloride injections
• Liposomal bupivacaine products
• Other long-acting local anesthetics
• Continuous peripheral nerve-block pumps
• Catheter-based analgesia
• Multimodal postoperative pain protocols
• New in situ depot formulations

The most direct product-level competitor is another long-acting local anesthetic intended for surgical-site administration. The most important commercial competitors may instead be lower-cost standard bupivacaine, liposomal bupivacaine, and non-drug analgesic technologies.

How does POSIMIR compare with standard and liposomal bupivacaine?

Factor	Standard bupivacaine	Liposomal bupivacaine	POSIMIR
Release profile	Immediate or short duration	Extended release	Extended release
Delivery vehicle	Aqueous solution	Liposome-based suspension	SAIB-based depot solution
Administration	Local infiltration or nerve block	Local infiltration	Surgical-site infiltration
Excipient complexity	Low	High	High
Manufacturing difficulty	Relatively low	High	High
Main cost pressure	Commodity generic pricing	Complex injectable economics	Platform and process economics
Substitution risk	High from generics	Moderate from other extended-release products	Moderate to high from alternative depots
Key technical barrier	Limited	Liposome manufacture and stability	Viscosity, depot formation, and solvent control

POSIMIR may compete effectively where a hospital values a single administration and reduced reliance on catheters, pumps, or repeated dosing. Its commercial performance depends on whether the product's acquisition cost is offset by reduced labor, shorter recovery workflows, lower opioid use, or fewer postoperative interventions.

What regulatory barriers affect POSIMIR-like excipients?

The principal regulatory risk is not simply whether SAIB is accepted as an excipient. FDA evaluates the complete formulation, route of administration, dose, local exposure, impurities, manufacturing process, and clinical performance.

A follow-on sponsor would likely need to address:

• Local tissue tolerance
• Systemic exposure to bupivacaine
• Benzyl alcohol exposure
• Ethanol exposure
• Residual solvents
• Depot persistence
• Sterility assurance
• Particulate matter
• Extractables and leachables
• Release-rate comparability
• Injection-site handling
• Product stability after manufacture

For a 505(b)(2) product, reliance on published data or the reference product may reduce development requirements, but the applicant would still need to establish product quality and clinical suitability for its proposed formulation.

What manufacturing and IP barriers create the strongest moat?

The strongest barriers are process-linked rather than ingredient-linked.

A competitor may obtain SAIB from the same commercial market, but still lack:

• A validated mixing sequence
• Control of solvent evaporation
• Consistent viscosity
• Reliable sterile filling
• Accurate drug distribution
• Predictable depot formation
• A validated release assay
• Compatible container-closure systems
• Clinical data for the intended surgical setting

These know-how assets may be protected through patents, trade secrets, regulatory filings, and manufacturing controls. A supplier that provides only SAIB has lower strategic value than a supplier that provides the excipient, analytical package, process support, and regulatory documentation.

What commercial opportunities exist outside the United States?

International expansion could support regional licensing, local manufacturing, and excipient supply agreements. The main targets are markets with:

• High surgical volume
• Rising demand for outpatient procedures
• Established local-anesthetic use
• Hospital interest in opioid-sparing care
• Regulatory pathways for hybrid or abridged products
• Local contract-manufacturing capacity

Geographic expansion may require separate evaluation of SAIB as a parenteral excipient, impurity limits, solvent labeling, and local requirements for depot injectables. A US approval does not automatically establish regulatory acceptance of the same excipient grade in every jurisdiction.

What revenue exposure does POSIMIR create?

POSIMIR's revenue exposure is concentrated in elective and high-volume surgical specialties. Commercial uptake depends on reimbursement, hospital formulary placement, surgeon preference, procedure-specific outcomes, and the product's cost relative to standard bupivacaine and liposomal bupivacaine.

For excipient and manufacturing companies, the revenue opportunity is likely to be more durable when tied to multiple products. A single-product supply agreement creates concentration risk. A platform agreement covering additional depot anesthetics, veterinary products, or regional formulations provides a broader revenue base.

Key Takeaways

• POSIMIR uses a SAIB-based SABER delivery system to provide extended-release bupivacaine.
• SAIB is the most commercially important excipient because it drives depot formation and release behavior.
• The strongest supplier opportunity is qualified injectable-grade SAIB supported by analytical, regulatory, and manufacturing services.
• Sterile fill-finish for viscous, solvent-containing formulations is a specialized opportunity.
• POSIMIR-like products face barriers involving viscosity control, depot performance, local tolerability, container compatibility, and process know-how.
• Direct competition includes liposomal bupivacaine and other long-acting local anesthetics, while generic standard bupivacaine creates substantial price pressure.
• Patent and generic-entry analysis requires current review of Orange Book listings, USPTO records, and Paragraph IV litigation.
• The best commercial strategy is a multi-product platform license or supply agreement rather than dependence on POSIMIR alone.

FAQs About POSIMIR Excipients and Commercial Strategy

Is sucrose acetate isobutyrate safe for injectable use?

POSIMIR's FDA approval establishes the safety of its complete formulation for the approved use and route. The approval does not mean that every SAIB grade is interchangeable for parenteral use. Injectable applications require product-specific control of purity, impurities, sterility, and local tolerability [1].

Can a generic company substitute another depot-forming excipient for SAIB?

Yes, a competitor could develop a different delivery system, but it would need to establish quality, release performance, safety, and clinical suitability. Substitution would not eliminate the need to address POSIMIR-related patents or method-of-use rights.

Does POSIMIR compete directly with EXPAREL?

Both products target extended postoperative analgesia, but their delivery systems differ. EXPAREL uses liposomal bupivacaine, while POSIMIR uses a SAIB-based depot formulation. The commercial comparison depends on duration, administration technique, procedure-specific outcomes, acquisition cost, and hospital economics.

Could SAIB suppliers license their own depot platform?

Yes. A supplier with formulation know-how, analytical methods, manufacturing process control, and regulatory data could license a broader SAIB-based delivery platform. The license would have greater value if it covered multiple active ingredients and therapeutic areas.

Are POSIMIR biosimilars possible?

No. POSIMIR is a chemically synthesized small-molecule drug product, not a biologic. The relevant follow-on pathways are an ANDA or 505(b)(2) application, subject to the reference product's patents, exclusivity, formulation differences, and FDA requirements.

References

1. U.S. Food and Drug Administration. (2021). POSIMIR (bupivacaine hydrochloride) injection, prescribing information. FDA.

2. DURECT Corporation. (2023). Annual report and corporate disclosures concerning POSIMIR and the SABER delivery system. DURECT Corporation.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.